18572247. SYNTHESIS OF COVALENT PROTEIN DIMERS THAT CAN INHIBIT MYC-DRIVEN TRANSCRIPTION simplified abstract (Massachusetts Institute of Technology)

SYNTHESIS OF COVALENT PROTEIN DIMERS THAT CAN INHIBIT MYC-DRIVEN TRANSCRIPTION

Organization Name

Massachusetts Institute of Technology

Inventor(s)

ANDREI Loas of CAMBRIDGE MA (US)

BRADLEY L. Pentelute of REVERE MA (US)

SEBASTIAN Pomplun of CAMBRIDGE MA (US)

MUHAMMAD Jbara of CAMBRIDGE MA (US)

CARLY KATHERINE Schissel of CAMBRIDGE MA (US)

JACOB JOSHUA LEE Rodriquez of SOMERVILLE MA (US)

STEPHEN LEFFLER Buchwald of NEWTON MA (US)

ANN Boija of CAMBRIDGE MA (US)

ISAAC Klein of CAMBRIDGE MA (US)

SUSANA WILSON Hawken of CAMBRIDGE MA (US)

CHARLES HAN Li of CAMBRIDGE MA (US)

SYNTHESIS OF COVALENT PROTEIN DIMERS THAT CAN INHIBIT MYC-DRIVEN TRANSCRIPTION - A simplified explanation of the abstract

This abstract first appeared for US patent application 18572247 titled 'SYNTHESIS OF COVALENT PROTEIN DIMERS THAT CAN INHIBIT MYC-DRIVEN TRANSCRIPTION

The disclosure pertains to covalent protein dimers of MYC, MAX, and Omomyc; pharmaceutical compositions containing the covalent protein dimers; methods of producing the covalent protein dimers; and methods of treating disorders associated with MYC dysregulation (e.g., cancer) with the covalent protein dimers.

• Covalent protein dimers of MYC, MAX, and Omomyc are the focus of this patent application.
• Pharmaceutical compositions incorporating these covalent protein dimers are described.
• Methods for creating the covalent protein dimers are outlined in the patent application.
• The application also covers methods for utilizing the covalent protein dimers to treat disorders linked to MYC dysregulation, such as cancer.
• This innovation has the potential to revolutionize the treatment of MYC-related disorders, particularly cancer.

Potential Applications

The technology described in this patent application could have various applications in the field of oncology, specifically in the treatment of cancers associated with MYC dysregulation. Additionally, it may have implications for other disorders where MYC plays a role.

Problems Solved

This technology addresses the challenge of effectively targeting MYC dysregulation, a key factor in the development and progression of certain cancers. By creating covalent protein dimers of MYC, MAX, and Omomyc, this innovation offers a novel approach to treating these disorders.

Benefits

The benefits of this technology include the potential for more targeted and effective treatments for MYC-related disorders, particularly cancer. By specifically targeting MYC dysregulation with covalent protein dimers, this innovation may lead to improved patient outcomes and reduced side effects compared to traditional treatments.

Commercial Applications

Title: Innovative Covalent Protein Dimers for Targeted Cancer Therapy This technology could have significant commercial applications in the pharmaceutical industry, particularly in the development of novel cancer therapies. The market implications include the potential for new treatment options for patients with MYC-related cancers, as well as opportunities for partnerships and collaborations in the oncology sector.

Questions about Covalent Protein Dimers

What are the potential implications of using covalent protein dimers in cancer therapy?

Covalent protein dimers could offer a more targeted approach to treating MYC-related cancers, potentially leading to improved efficacy and reduced side effects compared to traditional treatments.

How do covalent protein dimers of MYC, MAX, and Omomyc differ from other therapeutic approaches targeting MYC dysregulation?

These covalent protein dimers represent a novel strategy for addressing MYC dysregulation, offering a unique mechanism of action that may enhance treatment outcomes for patients with MYC-related disorders.

Original Abstract Submitted

The disclosure relates to covalent protein dimers of MYC, MAX, and Omomyc; pharmaceutical compositions comprising the covalent protein dimers; methods of making the covalent protein dimers; and methods of treating disorders associated with MYC dysregulation (e.g., cancer) with the covalent protein dimers.